ISOLUTE® PLD+ plate were introduced, combining protein and phospholipid removal prior to LC-MS/MS.The website was re-built from scratch and launched on October 1st.A new instrument manufacturing facility was inaugurated in Wales, moving production in-house and providing improved control of the building and quality assurance processes.Biotage brings mass detection to flash chromatography with Isolera™ Dalton, the first commercial product to add mass detection to the purification process in one system.Launch of ISOLUTE® Myco, a convenient and effective sample preparation product targeting mycotoxin in foodstuffs.Biotage® Extrahera™ automated sample processor launched in October.The evolved concept for flash purification, ACI™ Accelerated Chromatographic Isolation, was introduced in June.Biotage commenced direct sales in South Korea via the Company’s newly started sales company in Seoul.Biotage invested SEK 19M for approximately 22 percent of the shares in the Danish company Chreto ApS, as part of its strategic investment in the purification of biomolecules.Launch of ISOLUTE and EVOLUTE On-line SPE cartridges for integrated SPE-HPLC systems.Biotage launched the updated evaporation system Biotage®V-10 Touch.Biotage expanded the analytical sales organization to cover Italy.ISOLUTE® Filter+ high performance filtration plates launched.Release of Biotage® SNAP Bio flash cartridges for purification of peptides.Launch of a new TurboVap® product line with totally revamped technology and functions.Launch of ISOLUTE® DME+ for removal of matrix components and hydrolysis enzyme from urine samples, using a simple pass through workflow.Biotage aqcuired Horizon Technology and their range of environmental sample preparation products.Launch of the Biotage® Sfär range of flash purification columns.Launch of the Biotage® Selekt flash purification system.Acquired PhyNexus and their automated high-throughput protein and plasmid purification technology.Through years of acquisitions and merges, that business evolved into what Biotage is today: a global company dedicated to developing high quality products for advancements in life science. Personal Chemistry was formed as Labwell AB in 1997, and has raised $14 million in two previous funding rounds.Our story goes back as far as 1969, when a small start-up in Wales pioneered a range of columns and consumables for GC and LC. In June, the company was forced to pull a $50 million listing on the Stockholm Exchange due to a misunderstanding over patents. ¿Personal Chemistry AB, of Uppsala, Sweden, has raised Krona 178 million (US$18.8 million) in a private placing whose proceeds accelerate the commercialization of Coherent Synthesis, a laboratory bench system for rapid chemical synthesis using microwaves. The three drugs, sold mainly to hospitals, have a combined turnover of #3 million in UK and Ireland. CeNeS is paying #10 million (US$14.1 million) in cash to Glaxo Wellcome plc, of London, for Diconal and Cyclimorph, both analgesics, and Valoid, for countering nausea caused by opioid analgesics. ¿ CeNeS Pharmaceuticals plc, of Cambridge, England, has acquired UK and Ireland rights to three drugs that it says will form the first stage of a pharmaceutical business that will help fund the company's central nervous system and pain control drug development programs.
0 kommentar(er)
